Merck's HS Treatment Candidate Shows Promise in Positive Trial Results

Pharmaceutical giant Merck has announced positive results from a Phase 2b trial of its investigational monoclonal antibody, tulisokibart, for the treatment of hidradenitis suppurativa (HS). The study met its primary endpoint, achieving a significant reduction in symptoms at week 16. The data showed that 72% of patients receiving high-dose tulisokibart achieved HiSCR50, compared to 35% in the placebo group.

The trial also demonstrated improvements in quality of life for those treated with tulisokibart, with mean reductions from baseline of -5.62 and -3.50 in the high- and medium-dose groups, respectively. Adverse events were reported in approximately half of all participants, but no serious or opportunistic infections occurred.

Tulisokibart targets tumor necrosis factor-like cytokine 1A and is being evaluated in six disease indications, including ulcerative colitis and Crohn's disease. The results of this trial provide valuable insights into the potential efficacy of tulisokibart for treating HS, a condition that affects approximately 1 in 100 people worldwide.